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Abstract
Cervarix vaccine was included in the National Immunization Program of Argentina in 2011 but
data about the local distribution of human papillomavirus (HPV) infection in women exposed to
the virus are scarce. This cross-sectional study determined the prevalence and type distribution of
HPV infection in unvaccinated women attending routine gynaecological screening in two public
hospitals located in Buenos Aires and Santa Fe, Argentina. Socio-demographic, sexual behaviour
and co-factors information was obtained from all participants (Buenos Aires, n=429; Santa Fe,
n=433). Cervicovaginal swabs were tested with an MY11/09 primer-based assay and with the
CUT primer system targeting mucosal/cutaneous HPVs.
Participants from Buenos Aires showed significantly higher rates of HPV infection (52.4% vs.
40.6%), of multiple infections (24.2% vs. 16.4%), and of low-risk (20.3% vs. 13.9%) and high-
risk types (44.1% vs. 33.3%) than those from Santa Fe. HPV-66 (Buenos Aires: 17%) and
HPV-16 (Santa Fe: 8.5%) were the most prevalent types. Novel HPV-66 putative subtype and
variants were identified. Vaccine types 16 and 18 were frequent (Buenos Aires: 13.5%; Santa Fe
F: 10.2%) but few participants had co-infections with both (Buenos Aires: 1.4%; Santa Fe: 0.2%).
A common risk factor for HPV infection was having a new sexual partner in the last year (Buenos
Aires: OR 2.53, p<0.001; Santa Fe: OR 1.85, p=0.04). This study provides valuable baseline data
for future assessment of the impact of massive vaccination in Argentina and it underlines the use
of additional HPV testing strategies, such as the CUT system, for surveillance and vaccinology.
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INTRODUCTION
Human papillomavirus (HPV) infection is a well-established cause of cervical cancer and
there is growing evidence that HPV is a relevant factor in other anogenital and head and
neck cancers [zur Hausen, 2002]. HPVs are DNA viruses perfectly adapted to the
differentiating epithelial cells of skin or mucosa, which exploit the cellular machinery for
their own purposes [Longworth and Laimins, 2004].
HPVs have been divided into 5 genera (Alpha, Beta, Gamma, Mu, and Nu) according to the
phylogenetic relationships of their complete L1 gene sequences [de Villiers et al., 2004].
More than 40 HPV types have been identified infecting the genital tract and they have been
grouped into the Alpha genus [de Villiers et al., 2004]. In addition, genital HPVs have been
divided into low-risk (LR) and high-risk (HR) HPV types depending upon their association
with the development of benign (condylomas) and malignant anogenital lesions, respectively
[zur Hausen, 2002; Munoz et al., 2003].
Cervical cancer is the second most common cancer among women worldwide, with an
estimated 529,000 new cases and 275,000 deaths in 2008 [WHO/ICO, 2010]. About 86% of
the cases occur in developing countries, accounting for 13% of all cancers affecting women.
South America has some of the highest cervical cancer incidence and mortality rates in the
world, surpassed only by most regions of Africa and South-Central Asia [Ferlay et al.,
2010]. An estimation for 2008 showed Argentina as one of the countries with the lowest
incidence (17.5/100,000) and mortality (7.4/100,000) rates in South America (24.1/100,000
and 10.8/100,000, respectively) [WHO/ICO, 2010]. Cervical cancer ranks as the third most
frequent cancer among Argentinean women and the second among women between 15 and
44 years old [WHO/ICO, 2010].
Active recruitment for cervical scrrening is recommended in the Argentinean National
guidelines. However, the lack of population registries and postal systems deficiencies
constitute an obstacle to increasing screening coverage through invitation letters, as
implemented in several developed countries [Alliance for Cervical Cancer Prevention,
2004]. As a result, cervical screening in Argentina is opportunistic, performed mainly in
urban areas and usually through family planning and reproductive health care facilities
[Arrossi et al., 2010].
Two prophylactic HPV vaccines are currently being introduced in various countries:
Gardasil (Merck, Whitehouse Station, NJ), and Cervarix (GlaxoSmithKline Biologicals,
Rixensart, Belgium). Both vaccines offer protection against HR HPV types 16 and 18,
which are estimated to account for 71% of invasive cervical cancers globally [de Sanjose et
al., 2010]. Gardasil also offers protection for LR HPV types 6 and 11, which are responsible
for 90% of all genital warts [Villa, 2007]. Both vaccines have been approved for use in
Argentina, and Cervarix was included in the National Immunization Program in 2011.
About 20.1% of Argentinean women are estimated to harbour cervical HPV infection at any
given time [WHO/ICO, 2010]. These estimates came from women with normal cytology
residing in the cities of Concordia [Matos et al., 2003] and La Plata [Abba et al., 2003], with
HPV prevalence values ranging from 16% to 46%, respectively. These data indicate the
heterogeneous character of HPV prevalence throughout the country and highlight the need
for further studies about exposed women living in other areas of Argentina.
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HPV infection with genital types is a frequent sexually transmitted infection. In the vast
majority of cases, these infections are usually transient and do not necessarily lead to
clinically significant lesions of the cervical mucosa [Schiffman, 1994]. Therefore,
understanding the local distribution of type-specific HPV infection in women exposed to the
virus before the implementation of the vaccine provides valuable baseline data for future
assessment of the impact of massive vaccination in Argentina.
This work reports the first pre-vaccine type-specific prevalence of HPV infection in sexually
active women recruited during a routine gynaecological visit to two public hospitals located
in Central Argentina. This analysis was performed using two HPV detection and typing
methods: an MY11/09 primer-based assay [Chouhy et al., 2006], and the CUT primer
system previously applied for the identification of a wide range of skin-associated HPVs
from different genera [Chouhy et al., 2010]. The association between HPV infection and the
socio-demographic characteristics, sexual behaviour and co-factors of the participants was
explored.
MATERIALS AND METHODS
Subject recruitment and data collection
Between 2008 and 2010, sexually active women undergoing a routine gynaecological visit
were recruited to participate in this cross-sectional study in two public hospitals located in
Central Argentina: the Hospital-Escuela “Eva Perón”, a provincial general hospital located
in Granadero Baigorria city, province of Santa Fe, and the Hospital General de Agudos “Dr.
Teodoro Alvarez”, a municipal health centre located in Buenos Aires city. Both hospitals
participate in the National Family Planning and Reproductive Health Program, receiving
patients of median and low-income resources, with and without health insurance. The study
was approved by the bioethics committees of each hospital, and written informed consents
were obtained from all study participants. All procedures were in accordance with the
Helsinki Declaration.
Women attending a routine gynaecological visit, who were non-postpartum for the past 6
weeks, were not hysterectomized, had no treatment for intraepithelial cervical disease or
abnormal cytology within the past 18 months, and had not previously been vaccinated
against HPV infection, were approached to participate in the study. After informed consent
was obtained, a study questionnaire covering socio-demographics (age, country of birth,
current residence, working status, education), sexual behaviour (age at first intercourse,
lifetime number of sex partners, new sexual partner in the last year, contraceptive use and
type), and co-factors related to the development of cervical cancer (history of sexually
transmitted infections and tobacco use) was given by the interviewer [Almonte et al., 2008].
Specimen collection and processing
All women underwent a complete gynaecologic examination that included cervical cytology
(Pap smear) and HPV DNA testing. For cervical cytology, an Ayres spatula was used to
collect exocervical cells, and a conical cytobrush (Cervicep, Buenos Aires, Argentina) was
used to collect endocervical cells. Once Pap smear was performed, the cytobrush was kept in
0.8 ml PBS solution for HPV DNA testing and processed as has been previously described
[Chouhy et al., 2006].
Cytological results were classified according to the Bethesda system 2001 [Solomon et al.,
2002]. The following classes were distinguished: negative for intraepithelial lesions and
malignancies (normal), atypical squamous cells of undetermined significance (ASC-US),
low-grade squamous intraepithelial lesions (L-SIL), and high-grade squamous intraepithelial
lesions (H-SIL).
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HPV DNA testing
HPV DNA detection and typing was done by two HPV DNA testing methods: the
L1HPVPCR 16.4 assay, a modified version of a previously reported assay [Chouhy et al.,
2006], and the CUT primer system [Chouhy et al., 2010]. A thermal cycler (Mastercycler
Personal Eppendorf, Hamburg, Germany) was used in all the experiments involving PCR.
L1HPVPCR 16.4 assay—This MY11/MY09 primers-based test [Manos et al., 1989] was
optimized for the simultaneous detection of HPV DNA and β-globin sequences in order to
determine HPV status and sample integrity in a single reaction. MY11 and MY09 primers
corresponded to nt 6,582–6,601 and 7,014–7,033, respectively, of the HPV-16 genome
(AF125673). Briefly, 45 μl of a PCR mixture containing 2.5 U of Taq DNA polymerase
(Fermentas, St. Leon-Rot, Germany), 1X PCR buffer, 2.75 mM MgCl2, 0.3 mM
deoxynucleoside triphosphates, HPV amplification primers [0.8 μM of MY11, 0.4 μM of
each anti-sense MY09 and MYGC09 (5′-cgacccarwggaaaytgatc-3′), both biotinylated at the
5′ ends] and β-globin amplification primers (0.12 μM of each PC04 and GH20) were
prepared [Saiki et al., 1986]. A 5 μl aliquot of sample lysate was added to the PCR mixture
and amplified using the following thermal profile: 2 min of initial denaturation at 95°C
followed by 40 cycles of 40 s at 94°C, 40 s at 52°C, 40 s at 72°C, and a final extension of 5
min at 72°C. Each PCR run included the following controls: a positive control (a pool of
1,000–10,000 copies/reaction of plasmid controls for each HPV type analyzed in the assay),
a negative control [5 ng of human placental DNA (Sigma, Buenos Aires, Argentina)] and a
reagent control (H2O instead of sample).
Amplicons (10 μl) were first evaluated for β-globin and HPV bands with 2% agarose gel
electrophoresis and ethidium bromide staining. Valid samples (positive for the β-globin
gene) were hybridized with a generic probes cocktail, and detected colorimetrically to
identify HPV infection with the method described earlier [Chouhy et al., 2006]. In this case,
2.5 μl of each PCR product were added to 60 μl of hybridization buffer containing 6 pmol
of each probe. The generic probes cocktail was a mixture of fluoresceinated GPX [Manos et
al., 1989] and CHG (5′-ctgtwgtkgatacyacycgcagtac-3′) probes. A sample was considered
HPV-positive when its OD value after colorimetric detection was greater than the cut-off
value determined as 2.5 times the OD value of the HPV-negative control of that experiment,
as has been previously defined [Chouhy et al., 2006].
HPV-positive samples were typed for 14 HR HPV types (HPV types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 66, 68 and 73) and 2 LR HPV types (HPV types 6 and 11) using the same
protocol described earlier [Chouhy et al., 2006]. Probes used for typing were the following:
MYB-12 (HPV-6), MYB-13 (HPV-11), MYB95/MYB133 (HPV-16), WDB74/MYB130
(HPV-18), MYB128/AG111 (HPV-31), MYB16/MYB64 (HPV-33), MYB115/MY117
(HPV-35), MYB89/MYB90 (HPV-39), MYB69/MYB129_RC (HPV-45), BC51 (HPV-51),
MYB81 (HPV-52), CHG56 (HPV-56), CHG58/MYB179 (HPV-58), MYB83 (HPV-66),
MYB194/MYB191 (HPV-68) and CHG73 (HPV-73). BC51 (5′-cactgccactgctgcggtttc-3 ′ ),
C H G 5 6 ( 5 ′-gctaacctactggaggactgg-3 ′ ), C H G 5 8 ( 5 ′-gcactgaagtaactaaggaaggta-3′)
and CHG73 (5′-acaacgtatgccaactctaa-3′) probes were designed for this work. AG111 was
previously reported [Chouhy et al., 2006] and the rest were previously described [Manos et
al., 1989]. One or two oligonucleotide probes per type were used (4 pmol of each type-
specific probe). Hybridization temperatures in the liquid hybridization step were 55°C for
HPV-31, HPV-33 and HPV-35, and 40°C for the rest. A sample was considered positive for
a specific HPV type when its OD value after colorimetric detection was greater than the cut-
off value determined as 4 times the OD value of the HPV-negative control, as previously
defined [Chouhy et al., 2006].
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CUT primer system—Suitable specimens were tested with CUT primers [forward and
reverse CUT primers corresponded to nt 5,868–5,888 and 6,225–6,243, respectively, of the
HPV-16 genome (AF125673)], with a “hanging droplet PCR” amplification strategy, and
with HPV amplicon identification by electrophoresis in 2% agarose gel. Type determination
was done by direct sequencing as previously described [Chouhy et al., 2010]. DNA
sequencing was performed using sequencing facilities (Macrogen, Maryland Rockville, US)
with reverse primer CUT1BRv. Electropherograms with multiple overlapping sequences
were flagged as possible mixed infections. PCR products from such samples were cloned
into pGEM-T-Easy vector (Promega, Buenos Aires, Argentina) and identified by PCR using
M13 Fw/Rv primers. At least three recombinant clones were sequenced from each sample.
Sequence analysis and accession numbers
Sequences derived from the CUT amplification system were compared to available HPV-
sequences in the GenBank database using the BLAST server. The oncogenic risk associated
to each HPV type was defined according to the current taxonomic classification [de Villiers
et al., 2004; Schiffman et al., 2009]. Hence, types 16, 18, 26, 30, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 69, 70, 73 and 82 were considered HR HPVs, while types 6, 11, 32,
40, 42, 43, 44, 54, 61, 62, 71, 74, 81, 83, 84, 86, 87, 89, 91, 114, and CP6108 were
considered LR HPVs.
A novel putative HPV-66 subtype and variants were defined according to the current
taxonomic classification [de Villiers et al., 2004]. CUT-fragments sequences showing
sequence identities ranging from 90% to 98% were considered subtypes, and variants when
showing identities ranging from 98% to 99% with respect to any of the previously known
HPV-66 strains. In this analysis, full-length L1 ORF sequences from HPV-66 variants
available at the GenBank were used for comparison [GenBank accession numbers U31794.1
(prototype) and EF177182.1 to EF177191.1].
HPV subtype and variants candidate sequences identified in this study have been submitted
to the GenBank with the following accession numbers: RA-66b (JN122286), RA-66.1
(JN122285), RA-66.2 (JN122287), RA-66.3 (JN122288), RA-66.4 (JN122289), RA-66.5
(JN122290), RA-66.6 (JN122291) and RA-66.7 (JN122292).
Statistical analyses
Concordance between the CUT system and L1HPVPCR 16.4 assay for the total tested
population was determined by the Kappa Coefficient (K).
A descriptive analysis was done of the HPV infection and independent variables. Tests of
association between HPV infection and its co-factors, the socio-demographic and
behavioural characteristics, were based on the Wald χ2 statistics. Two separate logistic
regressions were used, one for each site.
Characteristics with a significance level of P < 0.25 based on Wald χ2 statistics, were
considered in a multivariate model. In order to assess the most appropriate categorization of
continuous variables that turned out significant in the multivariate logistic regression
analysis, they were plotted against the log odds of HPV. The selection of variables in the
final model was done using a purposeful selection of covariates based on the algorithm
proposed by Hosmer and Lemeshow [Hosmer and Lemeshow, 2000]. Potential confounding
variables and interactions were studied. Significance was evaluated at 0.1 alpha level. Model
fit was assessed using the Le Cessie-van Houwelingen normal test statistics for the
unweighted sum of squared errors.
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Statistical analyses were performed using R Development Core Team (2008). P-Values less
than 0.05 were regarded statistically significant.
RESULTS
In the Santa Fe hospital, 472 healthy women were enrolled from September 2008 to June
2009. From them, 433 (92%) samples suitable for PCR analysis were obtained. All
participants with suitable samples were born in Argentina, with a mean age of 31.6 years
(age range: 14 to 77 years), 10.6% were residing in Rosario city and 89.4% were living in 26
small cities distributed in the Southern Santa Fe province. Forty-one percent were employed
and 56.3% had reached high school (studied for more than 7 years). Thirty-three percent
were habitual tobacco users, and 9.5% reported a history of sexually transmitted infections.
Cytological results for this site were: 403 normal (93.1%), 14 ASC-US (3.2%), 14 L-SIL
(3.2%) and 2 H-SIL (0.5%).
In the Buenos Aires hospital, 456 healthy women were recruited from March 2009 to
August 2010; 429 of them (94%) had suitable samples for PCR analysis. Participants had a
mean age of 31.2 years (age range: 15 to 69 years), 81% were born in Argentina and 19% in
other South American countries (10% in Bolivia, 7% in Paraguay, 1.5% in Dominican
Republic and 0.5% in Peru). Eighty percent were inhabitants of Buenos Aires City and 20%
resided in the surrounding conurbation in the province of Buenos Aires. Fifty-five percent
were employed and 70% had reached high school. Twenty-two percent were habitual
tobacco users, and 9.3% reported a history of sexually transmitted infections. Cytological
results for this group of women were: 371 normal (86.5%), 23 ASC-US (5.4%), 32 L-SIL
(7.4%) and 3 H-SIL (0.7%).
Significant differences were found among women from each hospital regarding education (p
< 0.001), working status (p < 0.001), age of first sexual intercourse (p < 0.001), number of
lifetime sexual partners (p = 0.02), contraception method used (p < 0.001), tobacco use (p <
0.001) and cytological results (p = 0.01). Yet, women from both sites showed similarities for
variables associated with an increased risk of HPV infection such as mean age (p = 0.51),
new sexual partner in the last year (p = 0.23), and history of sexually transmitted infections
(p = 0.94). Detailed data on the characteristics of women from each site is available from the
authors.
HPV DNA test results and comparison
The frequency of HPV infection in the total tested population (n = 862) was determined
through hybridization with generic HPV probes and colorimetric detection for MY-derived
amplification (L1HPVPCR 16.4 assay), or by the presence of visible bands after
electrophoresis in 2% agarose gel (CUT system). HPV DNA was present in 46.5% of the
analyzed women (401/862). HPV DNA was detected more often by CUT (336/862) than by
MY primers (245/862) and this difference was found statistically significant (p < 0.0001). In
addition, 180 women were positive and 461 negative for HPV DNA by both tests, leading to
a general concordance of 74.4% (641/862) (K = 0.43; 95% CI, 0.37–0.49). HPV types were
determined by hybridization to type-specific probes (L1HPVPCR 16.4 assay) or by direct
sequencing (CUT system). At least one HPV type common to 123 women was found,
leading to a type-specific concordance of 68.3% (123/180) between both tests.
The capacity of each HPV DNA testing strategy for detecting HPV types from different
species within the Alpha genus is summarized in Table I. Overall, both assays detected 743
viruses corresponding to 40 HPV types, 21 HR (species 5, 6, 7, 9 and 11) and 19 LR HPV
types (species 1, 3, 8, 10, 13 and 14). Altogether, these results indicate that both assays used
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in combination comprehensively cover all mucosal HPV types involved in genital
infections.
Overall HPV DNA prevalence and factors associated with HPV infection
HPV frequencies were explored using both HPV testing strategies in combination. Table II
shows the socio-demographic and sexual behaviour information and related co-factors
associated with HPV infection in this study or according to others [Almonte et al., 2008].
Participants from Buenos Aires showed a significantly higher rate of HPV infection with
respect to those from Santa Fe (52.4% Vs 40.6%, p < 0.001). Regarding age groups, women
aged 15–23 years showed the highest HPV prevalence in Buenos Aires (64.2%, p = 0.02). In
contrast, women aged 31–47 years showed the lowest rates of HPV infection in Santa Fe
(31.3%, p = 0.03), with an increasing trend in the lower and upper age intervals. Women
who had more than 3 sexual partners in their lifetime (Buenos Aires, p = 0.07; Santa Fe, p =
0.001), and those who had a new sexual partner in the last year (Buenos Aires, p < 0.001;
Santa Fe, p = 0.001) showed higher rates of HPV infection. On the other hand, HPV
prevalence in both sites did not vary significantly with respect to other socio-demographics
(education and working status), nor to age at first sexual intercourse, nor to the kind of
contraceptive used or to co-factors related to the development of cervical cancer.
Those variables associated with HPV DNA detection at p < 0.25 in the univariate analysis
were examined with the multivariate logistic regression analysis (Table II). According to the
multivariate analysis (Table III), only women aged below 24 years and those who had a new
sexual partner in the last year showed a higher chance of HPV infection in Buenos Aires.
For women from Santa Fe, only one variable was associated with HPV infection after
multivariate analysis (Table III): women who had a new sexual partner in the last year had a
higher chance of HPV infection than those that did not. The variable “number of lifetime
sexual partners” remained in the final model because it was found to be slightly
confounding.
HPV type distribution according to cytology by site
Table IV shows the overall distribution of HPV genotypes in each hospital according to
cytology. In general, women from Buenos Aires showed higher frequencies and wider
distribution of HPV genotypes than those from Santa Fe. HPV prevalence and HR HPV
prevalence increased according to cytological diagnosis severity in both hospitals. HPV-66
was the most prevalent type overall (17%) and also in most cytological diagnosis in Buenos
Aires, whereas HPV-16 (8.5%) was the most common type overall in Santa Fe.
With respect to LR HPV types, HPV-43 (3.7%) was the most common type in Buenos
Aires, while no particular type predominated in Santa Fe. With respect to the most common
types detected in each site, HR HPV types 16, 31, 39, 52, 56, 58 and 66 were found in both
sites but with different frequencies (Fig. 1). HPV-18 and HPV-68 were among the most
common types in Buenos Aires (Fig. 1A) but they did not appear in Santa Fe (Fig. 1B). The
same was true for HR HPV types 33 and 51 in Santa Fe (Fig. 1). There was a statistically
significant difference in the frequency of HPV-66 between hospitals (Buenos Aires: 17%;
Santa Fe: 7.2%; p = 0. 0001).
Frequencies of specific types and multiple infections in each hospital are shown in Fig. 2.
Overall, women from Buenos Aires showed higher frequencies with respect to those from
Santa Fe regarding HPV infection (52.4% vs. 40.6%; p < 0.001), multiple infections (24.2%
vs. 16.4%; p = 0.005), HR HPV types (44.1% vs. 33.3%; p = 0.001) and LR HPV types
(20.3% vs. 13.9%; p = 0.01). Participants from Buenos Aires also showed higher
frequencies of the vaccinal types 6/11/16/18 (15.4% vs. 12.9%) and of the 5 most
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carcinogenic types 16/18/31/33/45 (19.3% vs. 17.6%) with respect to those from Santa Fe,
but these differences were not found to be statistically significant.
Most participants contained a single HPV type [Buenos Aires: 28.2% (121/429); Santa Fe:
24.2% (105/433)] while most co-infections involved 2 HPV genotypes [Buenos Aires:
11.9% (51/429); Santa Fe: 8.3% (36/433)] in both sites. However, multiple infections with 3
HPV types [Buenos Aires: 5.6% (24/429); Santa Fe: 5.1% (22/433)] and with 4 or more
HPV genotypes [Buenos Aires: 6.7% (29/429); Santa Fe: 3.0% (13/433)] were also common
in both hospitals.
Overall, vaccinal HPV types 16 and/or 18 were present as single infections and also in
combination with other HPV types in women from both sites [Buenos Aires: 13.5%
(58/429); Santa Fe: 10.2% (44/433)]. However, few participants at each hospital had HPV
types 16/18 included in Cervarix [Buenos Aires: 1.4% (6/429); Santa Fe: 0.2% (1/433)] and
none had all HPV types 6/11/16/18 included in Gardasil.
HPV-66 Genomic Diversity
In view of the high prevalence of HPV-66 found in this study, the genomic diversity of the
CUT fragments identified in each site was explored. Ninety HPV-66 CUT fragments with
clear cromatograms were selected from samples presenting single infections, or multiple
infections that were subsequently cloned and sequenced.
Sequence comparisons of the HPV-66 CUT fragments revealed that 20/90 sequences (18
from Buenos Aires; 2 from Santa Fe) showed complete sequence identity to the HPV-66
prototype (U31794.1), while 54/90 sequences (32 from Buenos Aires; 22 from Santa Fe) had
complete sequence identity to the EF177182.1 variant. In the remaining 16/90 sequences,
the first putative subtype and 7 novel putative variants were identified (Fig. 3A).
The putative subtype (RA-66b) was detected in a cervical sample from a 26-year old
Bolivian woman with normal cytology (patient BA035) recruited at the Buenos Aires
hospital. RA-66b showed nucleotide identities ranging from 90.7% to 92.2% (Fig. 3B),
resulting in 6 out of 89 (6.7%) amino acid changes (data not shown). The novel HPV-66
putative variants (isolates RA-66.1 to RA-66.7) showed nucleotide identities ranging from
96.3% to 99.6%. Of them, 2 putative variants were found in 3 women from Santa Fe
(RA-66.1, RA-66.3), 3 in 4 women from Buenos Aires (RA-66.4, RA-66.5, RA-66.7), and 2
in 6 women from both sites (RA-66.2, RA-66.6). The isolate RA-66.6 was the most common
HPV-66 putative variant. Finally, mixed infections in patients BA032 (RA-66.4, RA-66.5)
and SF241 (RA-66.2, RA-66.6) were also detected.
DISCUSSION
This was the first large-scale study to estimate the pre-vaccine HPV type-specific prevalence
in sexually active women attending a routine gynaecological visit in two hospitals located in
the most populated regions of Argentina. Since recruitment for the study was hospital-based,
the sample populations were not representative of the general population. However, given
that Argentina is a federation in which each province autonomously establishes its own
health policies such as funding and management of the health care services [Arrossi et al.,
2010], these results depict routine clinical practice in public hospitals of Argentina.
This investigation was done using two HPV testing strategies in combination: an MY09/11-
based test [Chouhy et al., 2006] and the CUT system [Chouhy et al., 2010]. The capacity of
each test for detecting HPV types was determined with respect to the total tested population.
The L1HPVPCR 16.4 assay detected 472 viruses corresponding to the 16 genotypes
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included in the assay, while the CUT system identified 401 viruses corresponding to 36
genotypes (17 HR and 19 LR HPV types, Table I). In addition, only 130 viruses (17.5%)
were simultaneously detected by both tests, indicating that the assays used in this study
complement each other and can be used in combination to explore the HPV types involved
in cervix infections.
The behaviour of HPV in the cervix is strongly correlated with phylogenetic categories
[Schiffman et al., 2009], and all HPV genotypes infecting the cervical mucosa are included
in the Alpha genus [de Villiers et al., 2004]. HR HPV types have been grouped into species
5, 6, 7, 9 and 11 while LR HPV types are grouped into species 1, 3, 8, 10, 13 and 14. The
CUT system identified viruses from 10 out of the 11 species containing mucosal types
(Table I). These results, together with the previous application of this system for identifying
skin-associated HPVs from Alpha-, Beta-, and Gamma-PV genera [Chouhy et al., 2010],
indicate that the CUT system is one of the up-to-date primers with the broadest capacity for
the detection of HPVs. This characteristic makes the CUT system an ideal tool to investigate
the epidemiology of HPV in different epithelia.
Several international studies have examined the prevalence of HPV in women. The diversity
of population samples, HPV amplification strategies and typing methods make it difficult to
identify studies that are exactly comparable to each other [Bosch et al., 2008]. In order to
avoid these limitations, identical study designs, recruitment protocols and HPV DNA testing
strategies were applied in both hospitals to investigate the geographical differences in HPV
prevalence and type distribution. With this approach, a significantly higher rate of HPV
infection was found in women from Buenos Aires (52.4%) than in those from Santa Fe
(40.6%). The same trend was observed in the frequencies of multiple infections, HR and LR
HPV types (Fig. 2). The high rates of HPV prevalence found in participants from both health
centres could be explained by the application of two HPV testing strategies in combination.
In particular, the CUT system was able to identify HPV types that are not usually targeted in
the assays used in most epidemiological studies (Table I) [Munoz et al., 2003; Bruni et al.,
2010; Eklund et al., 2010]. Considering that Buenos Aires and Santa Fe hospitals are
relatively close to each other (approximately 300 km), these results reflect the heterogeneous
nature of HPV prevalence throughout the country and are consistent with inter-regional
variations reported for other parts of the world [Bosch et al., 2008; Bruni et al., 2010]. On
the other hand, differences in the proportion of the cytological categories among women
attending to each hospital (Table IV) could partly explain the higher HPV prevalence found
in Buenos Aires. In fact, participants from Buenos Aires had a significantly higher
proportion of cervical abnormalities (ASC-US, L-SIL, H-SIL), mainly due to the higher
number of L-SIL cases (p = 0.01), than those from Santa Fe. Still, HPV infection rates
differed significantly by site in women with normal cytology (p = 0.0005), the most
represented cytological category (Table IV). Under these considerations, the significant
differences found in HPV prevalence between the two hospitals may be due to the different
lifestyles of big cities (Buenos Aires) and small towns (Santa Fe), as described before (e.g.
age at first sexual intercourse, number of lifetime sexual partners, etc).
Because HPV is a sexually transmitted agent necessary for carcinogenesis, sexual behaviour,
in combination with certain co-factors, is associated with an increased risk of infection
[Almonte et al., 2008]. In this report, the variables associated with HPV infection that were
significant in the univariate analysis in both sites were age and having new sex partners in
the last year (Table II). In the multivariate analysis, having a new sexual partner in the last
year remained a common risk factor for HPV infection in both hospitals (Table III). In
addition, women more than 24 years old showed a higher chance of HPV infection in
Buenos Aires. Nevertheless, the variables influencing HPV prevalence that were identified
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in each site were consistent with the typical risk factors associated with the acquisition of
HPV [Almonte et al., 2008].
Considering that most women in both sites had normal cytology (Buenos Aires: 86.5%,
Santa Fe: 93.1%) and the high HR-HPV rates found in this cytological category (Table IV),
HPV DNA testing may be considered for molecular surveillance in Argentina. In addition,
important differences related to HPV genotype distribution and frequencies were found
between both sites (Fig. 1). The fact that HPV-16 was the most frequent type found in Santa
Fe was predictable since it is the most common type everywhere and it also is the most
prevalent type in normal cytology [Bruni et al., 2010] as well as in cervical lesions of
different grade, including cervical cancer [de Sanjose et al., 2010]. However, finding
HPV-66 as the most frequent type in Buenos Aires was an unexpected result. Moreover, the
HPV-66 frequencies that were found in this study were among the highest reported
worldwide [Bruni et al., 2010; de Sanjose et al., 2010], and also among the recently
published prevalence studies in which this type was identified [Castellsague et al., 2012; da
Silva et al., 2012; Mazarico and Gonzalez-Bosquet, 2012]. These findings are due to the
application of the CUT primers that appeared to have a differential specificity with respect
to the MY11/09 primers (100/104 Vs 38/104, respectively) in detecting HPV-66 (Table I).
In addition, a systematic mistyping between HPV-56 and HPV-66 has been reported for
some commercial tests based on the MY11/09 primers and probes described by Manos and
col. [Manos et al., 1989]; for example, the Linear Array assay (Roche Diagnostics, Basel,
Switzerland) [Eklund et al., 2010]. This fact could affect the correct identification of the
types that are important in HPV surveillance and vaccinology.
HPV-66 is an Alpha-PV from species 6 originally detected in a 38-year old patient biopsy
with a stage I invasive squamous-cell carcinoma of the uterine cervix; it was classified as a
member of an HPV group associated with genital neoplasia, together with HPV-56
[Tawheed et al., 1991]. However, HPV-66 was considered a “probable” high-risk type due
to its low prevalence in cervical carcinomas [Munoz et al., 2003; Schiffman et al., 2009].
Based on the results obtained with the CUT system and the apparently lower efficiency of
the MY11/09 primers-based assays in detecting this type (Table I), it can be speculated that
HPV-66 frequency in epidemiological studies may be underestimated. On the other hand,
HPV-66 is not included as a target virus in the commercially available Hybrid Capture II
High-Risk HPV DNA Test (Qiagen, Hilden, Germany). These facts highlight the use of
alternative methods, like the CUT system, to elucidate whether HPV-66 is underestimated
due to the aforementioned difficulties in its detection or not, and also to corroborate its
epidemiological classification and carcinogenicity.
The existence of intra-type variants with different oncogenic potential and precise patterns
of geographic distribution has been documented for some HPV types, in particular for
HPV-16 and -18 [Bernard et al., 2006]. However, the understanding of the mechanisms that
give rise to new variants and types of HPV is still rudimentary. Since the identification of
HPV-66, 10 variants have been described whose complete genomes are available at the
GenBank. In addition, partial L1 gene sequences of about sixty putative HPV-66 variants
have been identified in different geographic areas [Cerqueira et al., 2003; Prado et al., 2005;
Castro et al., 2011; Wyant et al., 2011; Cento et al., 2012]. This study reports the first
HPV-66 putative subtype and 7 novel putative variants (Fig. 3). However, the presence of
additional variants in the 74 sequences with complete sequence identity to the known
HPV-66 prototype and variants cannot be excluded. Indeed, the HPV-66 prototype
(U31794.1) shows 100% identity to HPV-66L1Qv25662 (EF177186.1) variant, and the
HPV-66L1Qv35854 (EF177182.1) strain shares complete sequence identity to
HPV-66L1Qv26488 (EF177184.1), HPV-66L1Qv24220 (EF177189.1), HPV-66L1Qv11088
(EF177190.1), and HPV-66L1Qv218 (EF177191.1) variants in the CUT amplicon. On the
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other hand, most of the putative HPV-66 variants previously described [Cerqueira et al.,
2003; Prado et al., 2005; Castro et al., 2011; Wyant et al., 2011; Cento et al., 2012] are
sequences obtained with the MY9/MY11 primers that do not overlap with the CUT
amplicons. Further studies are required to assess the phylogenetic relationships of the novel
HPV-66 strains reported here with respect to those variants/putative variants described
previously. The characterization of the complete genomes of the novel putative subtype and
of the variants found in this study will help to advance in the knowledge of the diversity and
evolution of HPV-66. Moreover, the identification of differences and similarities between
HPV-66 and other related HPVs might eventually shed light on what makes particular types
trigger cancer, while others simply give rise to benign transformations. In conclusion, this
study provides relevant and timely data on the pre-vaccine type-specific prevalence of HPV
infection and associated-risk factors in sexually active women in Argentina which might be
useful for the future assessment of the impact of massive vaccination. The high rates of HPV
infection and the wide spectrum of types found in both groups of women support the need
for the implementation of virological and molecular surveillance to monitor the
epidemiological profile of HPV infection in the vaccine era. In this scenario, the ability
demonstrated by the CUT primer system in detecting viruses from most species of the Alpha
genus containing mucosal types suggests this testing strategy is a useful tool to explore the
HPV types involved in cervix infections.
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Fig. 1. Most frequent HPV types found in Buenos Aires (A) and Santa Fe (B) sites
Error bars indicate 95% confidence intervals. Grey bars and white bars indicate HR and LR
HPV genotypes, respectively.
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Fig. 2. Prevalence of HPV infection, specific types and multiple infections by site
Vaccinal types refer to the presence of any of the types included in the quadrivalent vaccine
against HPV (types 6, 11, 16, 18). Most carcinogenic types refer to the presence of at least
one of the 5 viruses (HPV types 16, 18, 31, 33, 45) most frequently found in invasive
cervical carcinomas [de Sanjose et al., 2010]. Error bars indicate 95% confidence intervals.
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Fig. 3. Genomic diversity of the novel HPV-66 putative subtype and variants
A. Nucleotide sequence variations among HPV-66 L1 sequences. L1 nucleotide positions
where variations were observed are written across the top. Positions that do not vary from
those of the HPV-66 prototype sequence are marked with dashes.
B. Pairwise nucleotide identities (%) of the novel putative subtype and variants with respect
to reference HPV-66 strains. Only HPV-66 variants with complete genomes available at the
GenBank database were considered as reference strains in the analysis. Patients from whom
each novel putative subtype and variants were identified are indicated below.
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TABLE III
Multivariate analysis of variables associated with HPV infection.
Buenos Aires (n = 429)
Odds ratio [95% CI] P value
Age, years
 15–23 1 (Referent)
0.02
 24–30 0.62 [0.36 – 1.06]
 31–47 0.48 [0.29 – 0.79]
 ≥ 48 0.54 [0.22 – 1.31]
New sexual partner in the last year
 No 1 (Referent)
< 0.001
 Yes 2.53 [1.53 – 4.27]
Santa Fe (n = 433)
Odds ratio [95% CI] P value
New sexual partner in the last year
 No 1 (Referent)
0.04
 Yes 1.85 [1.01 – 3.41]
[95% CI]: 95% confidence intervals
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